MS
MSB.AU Mesoblast Ltd
- Market cap
- AUD 2.93B
- P/E
- -
- P/B
- 3.64x
- ROE
- -10.3%
- Dividend yield
- -
- Fundamental score
- 2.0/5
Ratios use the latest price and the fiscal year ending Jun 2026.
Is MSB.AU undervalued?
Graham numberThe Graham number of Mesoblast Ltd cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Mesoblast Ltd fundamental analysis
9 of 21 checks passedROE 0/2
Low return on equity (-10.3%), below 10%.
ROA 1/1
Return on assets (-7.6%) is above the industry median (-51.4%).
Profit Consistency 0/2
Not profitable for at least 3 consecutive years.
Earnings Growth 5Y 1/1
Earnings per share grew over the past 5 years.
Earnings Acceleration 0/1
Not enough positive earnings history to compare last year's growth with the 5-year average.
Earnings Growth vs Industry 1/1
Last year's EPS growth (49.2%) is above the industry median (-5.3%).
Revenue Growth 2/2
Revenue grew 154.0% a year over the past 3 years.
Short-term Liquidity 1/1
Current assets cover short-term liabilities.
Long-term Liabilities 1/1
Current assets cover long-term liabilities.
Debt to Equity 2/2
Low debt to equity (22.4%), 40% or less.
Debt Trend 0/1
Debt to equity has risen over the past 5 years.
Cash Runway 1/2
Cash covers 1.1 years of the current cash burn.
PE vs Market 0/1
PE is negative or not available.
PE vs Industry 0/1
PE is negative or not available.
PBV 1/1
Price to book (3.6x) is below the industry median (4.4x).
Graham Number 0/1
Graham number needs positive earnings and book value.
PEG 0/1
PEG needs positive PE and positive 5-year earnings growth.
Dividend Yield 0/2
No dividend paid in the last reported year.
Dividend Stability 0/2
Dividends were not paid steadily for the past 5 years.
Dividend Growth 0/1
Dividends paid did not grow over the past 5 years.
Payout Ratio 0/1
No dividend, or no profit to pay it from.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
Mesoblast Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Mesoblast Ltd
Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia. The company's proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. It offers Ryoncil for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, Duchenne muscular dystrophy, and biologic refractory inflammatory bowel disease, as we…
Full company profileMesoblast Ltd financial statements
Mesoblast Ltd annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 2.41M | 17.3M | 16.7M | 32.2M | 7.46M | 10.2M | 7.50M | 5.90M | 17.2M | 123M |
| Gross Profit | -9.65M | 11.8M | -58.5M | -49.3M | -78.3M | -53.4M | -47.4M | -35.2M | 12.1M | 103M |
| Operating Income | -90.0M | -77.3M | -80.2M | -74.9M | -109M | -80.6M | -69.3M | -84.1M | -62.4M | -52.4M |
| EBITDA | -87.2M | -74.7M | -84.5M | -69.0M | -84.7M | -76.6M | -58.6M | -53.3M | -73.7M | -43.9M |
| Net Income | -76.8M | -35.3M | -89.8M | -77.9M | -98.8M | -91.3M | -81.9M | -88.0M | -102M | -58.8M |
| EPS | -0.14 | -0.08 | -0.17 | -0.14 | -0.16 | -0.14 | -0.11 | -0.09 | -0.09 | -0.05 |
| Balance Sheet | ||||||||||
| Total Assets | 656M | 692M | 652M | 734M | 745M | 662M | 669M | 669M | 785M | 773M |
| Total Liabilities | 139M | 146M | 171M | 184M | 163M | 165M | 168M | 189M | 187M | 205M |
| Shareholders' Equity | 517M | 546M | 481M | 549M | 581M | 497M | 502M | 480M | 597M | 568M |
| Cash & Short-term Investments | 45.8M | 37.8M | 50.4M | 129M | 137M | 60.0M | 70.9M | 62.6M | 161M | 47.4M |
| Total Debt | - | 59.4M | 81.3M | 99.3M | 105M | 107M | 116M | 119M | 128M | 127M |
| Cash Flow | ||||||||||
| Operating Cash Flow | -95.5M | -75.0M | -57.8M | -56.4M | -107M | -65.8M | -63.3M | -48.5M | -50.0M | -43.8M |
| Capital Expenditure | 311K | 201K | 279K | 2.25M | 1.65M | 232K | 314K | 331K | 730K | 898K |
| Free Cash Flow | -95.8M | -75.2M | -58.1M | -58.6M | -108M | -66.0M | -63.6M | -48.8M | -50.7M | -44.7M |
| Ratios | ||||||||||
| ROE | -14.9% | -6.5% | -18.7% | -14.2% | -17.0% | -18.4% | -16.3% | -18.3% | -17.1% | -10.3% |
| ROA | -11.7% | -5.1% | -13.8% | -10.6% | -13.3% | -13.8% | -12.2% | -13.1% | -13.0% | -7.6% |
| Net Profit Margin | -3,184.7% | -203.5% | -537.0% | -242.4% | -1,325.3% | -894.6% | -1,091.7% | -1,490.3% | -593.9% | -47.8% |
| Debt to Equity | - | 0.11x | 0.17x | 0.18x | 0.18x | 0.22x | 0.23x | 0.25x | 0.21x | 0.22x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Mesoblast Ltd dividends
Mesoblast Ltd has not paid dividends in the last 10 fiscal years.
Last stock split: 135:128 on Dec 5, 2023.
Who owns Mesoblast Ltd
- Insiders 36.72%
- Institutions 17.55%
- Public & others 45.73%
- Shares outstanding 1.30B
- Free float 832M
Top funds holding MSB.AU
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard International Stock Index-Total Intl Stock Indx | 7.33M | 1.13% | - | Oct 2020 |
| Vanguard Tax Managed Fund-Vanguard Developed Markets Index Fund | 3.16M | 0.49% | - | Dec 2020 |
| iShares Core MSCI EAFE ETF | 2.19M | 0.34% | - | Feb 2021 |
| iShares MSCI EAFE Small Cap ETF | 2.14M | 0.33% | - | Feb 2021 |
| DFA Asia Pacific Small Company Series | 1.56M | 0.24% | - | Jan 2021 |
| Vanguard Intl Equity Index Fds-FTSE All World ex U.S.Small Cap Index | 1.28M | 0.20% | - | Oct 2020 |
| iShares Core MSCI Total International Stock ETF | 742K | 0.11% | - | Feb 2021 |
| Schwab Strategic Tr-Schwab International Small Cap Equity ETF | 701K | 0.11% | - | Nov 2020 |
| College Retirement Equities Fund-Stock Account | 473K | 0.07% | - | Dec 2020 |
| Vanguard International Stock Index-Pacific Stock Index | 458K | 0.07% | - | Jan 2021 |
Mesoblast Ltd company profile
- Company name
- Mesoblast Ltd
- Ticker
- MSB.AU
- ISIN
- AU000000MSB8
- Exchange
- Australian Securities Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 108
- Fiscal year end
- June
- Address
- 55 Collins Street, Melbourne, VIC, Australia, 3000
- Phone
- 61 3 9639 6036
- Website
- mesoblast.com
About Mesoblast Ltd
Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia. The company's proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. It offers Ryoncil for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, Duchenne muscular dystrophy, and biologic refractory inflammatory bowel disease, as well as ulcerative colitis and Crohn's disease; Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease; and Revascor for the treatment of hypoplastic left heart syndrome. The company is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; MPC-150-IM for the treatment or prevention of chronic heart failure; Ryoncil for the treatment of pediatric SR-aGVHD; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM; Grünenthal GmbH to develop and commercialize MPC-06-ID for the treatment of chronic low back pain due to degenerative disc disease in patients; and JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa and for the treatment of neonatal hypoxic ischemic encephalopathy. Mesoblast Limited was incorporated in 2004 and is headquartered in Melbourne, Australia.
Mesoblast Ltd management
10- Dr. Silviu Itescu FACP, FACRA, FRACP, MBBS (Hons)Founder, CEO, MD, Chairman of Scientific Advisory Board & Executive Director · born 1957
- Dr. Eric A. Rose M.D.Chief Medical Officer & Executive Director · born 1951
- Mr. Paul Hughes BPHARMGlobal Head of Corporate Communications & Joint Company Secretary
- Mr. Anthony WhealHead of Human Resources
- Dr. Paul J. Simmons BSc, Ph.D.Scientific Advisor to the Chief Executive Officer · born 1959
- Ms. Geraldine Storton B.Sc., M.B.A., MMSHead of Regulatory Affairs & Quality Management
- Mr. Daniel Devine B.Sc., J.D., M.B.AHead of Special Projects
- Mr. Justin Horst B.S.Head of Manufacturing
- Dr. Fiona See Ph.D.Senior VP & Head of Translational Research
- Mr. Marcelo SantoroChief Commercial Officer